Related Experiment Video
Updated: Jun 26, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Recent advances in obesity pharmacotherapy
Marcos A Mayer1, Christian Höcht, Ana Puyó
1Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín, 956, (C1113AAD) Buenos Aires, Argentina. marcos.mayer@gmail.com
Current Clinical Pharmacology
|January 20, 2009
Summary
Obesity pharmacotherapy aids weight reduction and improves health, but achieving long-term goals remains challenging. This review covers current anti-obesity drugs and future therapeutic options.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Obesity is a global epidemic requiring effective interventions.
- Lifestyle changes alone are often insufficient for sustainable weight loss.
- Pharmacotherapy is a crucial component in managing obesity and its associated risks.
Purpose of the Study:
- To review the characteristics of existing anti-obesity medications.
- To explore emerging anti-obesity agents for future clinical application.
Main Methods:
- Literature review of approved anti-obesity drugs.
- Analysis of mechanisms of action and safety profiles.
- Exploration of novel therapeutic targets and agents.
Main Results:
- Current anti-obesity drugs demonstrate efficacy in weight reduction and cardiometabolic risk improvement.
- Variations exist in drug mechanisms, safety profiles, and long-term effectiveness.
- Challenges persist in achieving and maintaining therapeutic objectives.
Conclusions:
- Available anti-obesity agents offer valuable tools for weight management.
- Further research into novel agents is essential for improved long-term patient outcomes.
- Personalized therapeutic strategies may enhance the effectiveness of obesity pharmacotherapy.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...